Viking Therapeutics Inc (NASDAQ:VKTX) Expected to Post Earnings of -$0.13 Per Share

Analysts predict that Viking Therapeutics Inc (NASDAQ:VKTX) will post ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.11). Viking Therapeutics reported earnings per share of ($0.11) during the same quarter last year, which suggests a negative year-over-year growth rate of 18.2%. The company is expected to issue its next quarterly earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.61) to ($0.40). For the next financial year, analysts forecast that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.96) to ($0.47). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02).

A number of analysts recently issued reports on VKTX shares. ValuEngine raised Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Viking Therapeutics in a research report on Friday, August 2nd. BidaskClub cut Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 6th. Stifel Nicolaus started coverage on Viking Therapeutics in a research report on Tuesday, June 25th. They set a “buy” rating and a $14.00 price objective for the company. Finally, Oppenheimer started coverage on Viking Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a sell rating, twelve have given a buy rating and two have issued a strong buy rating to the company. Viking Therapeutics has a consensus rating of “Buy” and a consensus price target of $20.53.

Several large investors have recently made changes to their positions in the business. BlackRock Inc. grew its position in shares of Viking Therapeutics by 22.4% during the fourth quarter. BlackRock Inc. now owns 4,099,406 shares of the biotechnology company’s stock worth $31,361,000 after buying an additional 749,505 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Viking Therapeutics by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 387,039 shares of the biotechnology company’s stock worth $2,960,000 after purchasing an additional 1,555 shares during the last quarter. Northern Trust Corp lifted its stake in Viking Therapeutics by 18.5% during the fourth quarter. Northern Trust Corp now owns 728,958 shares of the biotechnology company’s stock worth $5,576,000 after purchasing an additional 113,995 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Viking Therapeutics during the fourth quarter worth approximately $1,478,000. Finally, Stifel Financial Corp lifted its stake in Viking Therapeutics by 30.7% during the fourth quarter. Stifel Financial Corp now owns 22,314 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 5,237 shares during the last quarter. 62.91% of the stock is owned by institutional investors.

Shares of VKTX stock traded down $0.20 on Friday, reaching $6.83. 11,380 shares of the company’s stock traded hands, compared to its average volume of 2,445,925. Viking Therapeutics has a 12-month low of $6.68 and a 12-month high of $24.00. The company has a market capitalization of $507.64 million, a P/E ratio of -17.12 and a beta of 2.29. The company has a 50 day moving average of $7.90.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Recommended Story: What is a blue-chip stock?

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.